newsfilter
← Latest News
Business Wire·

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

- Completed a comprehensive set of financing transactions in October 2025, securing access to up to $889 million of potential capital across equity, royalty, and credit - ­­ - Successful October submission of Biologics